Peptide carrier fusion proteins as allergy vaccines
The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.
1. A polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 149, SEQ ID No. 150, SEQ ID No. 151 and SEQ ID No. 152.
2. A composition comprising the polypeptide according to claim 1 and at least one of an adjuvant, a pharmaceutically acceptable excipient and a preservative.
3. A method f treating an allergy in a human or an animal in need thereof, comprising administering the polypeptide of claim 1 to the human or an animal.
4. A method of treating an allergy in a human or an animal in need thereof, comprising administering the composition of claim 2 and wherein the composition comprises a mixture of more than one polypeptide.
5. The polypeptide of claim 1 , comprising SEQ ID No. 14.
6. The polypeptide of claim 1 , comprising SEQ ID No. 15.
7. The polypeptide of claim 1 , comprising SEQ ID No. 16.
8. The polypeptide of claim 1 , comprising SEQ ID No. 17.
9. The polypeptide of claim 1 , comprising SEQ ID No. 18.
10. The polypeptide of claim 1 , comprising SEQ ID No. 19.
11. The polypeptide of claim 1 , comprising SEQ ID No. 20.
12. The polypeptide of claim 1 , comprising SEQ ID No. 149.
13. The polypeptide of claim 1 , comprising SEQ ID No. 150.
14. The polypeptide of claim 1 , comprising SEQ ID No. 151.
15. The polypeptide of claim 1 , comprising SEQ ID No. 152.
16. The composition of claim 2 , comprising SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, and SEQ ID No. 17.
17. The method of claim 4 , wherein the composition comprises SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, and SEQ ID No. 17.